Holdings Information

Bibliographic Record Display

• Author/Creator:Aptsiauri, Natalia.
  
• Title:MHC Class I Antigens In Malignant Cells [electronic resource] : Immune Escape And Response To Immunotherapy / by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera.
  
• ISBN:9781461465430
  
• Published/Created:New York, NY : Springer New York : Imprint: Springer, 2013.
  
• Physical Description:VIII, 51 p. 17 illus., 14 illus. in color. digital.
  
• Links:Online book
  

• Yale Holdings

  Holdings Record Display

  • Location:Yale Internet Resource
    Information about Off Campus Access
    
    
  • Call Number: None
    
  • Status:No information available 
  • Notes: Online Resource
    

   
• Local Notes:Access is available to the Yale community.
  
• Access and use:Access restricted by licensing agreement.
• Summary:Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​  
  
• Variant and related titles:Springer ebooks.
  
• Other formats:Printed edition:
  
• Format:Book
• Series:SpringerBriefs in Cancer Research ; 6
  SpringerBriefs in Cancer Research ; 6.
  
• Contents:​Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
  
• Subjects:Medicine.
  Oncology.
  Immunology.
  
• Also listed under:Garcia-Lora, Angel Miguel.
  Cabrera, Teresa.
  SpringerLink (Online service)